Contact us

Pathologists

Precision You Can Trust – In Your Lab or Through Our Network​

Using EndoPredict means reliable results1-11, fast turnaround, and ESMO Level 1A12 evidence – run locally with full support.​

Performed Locally, Accessible Globally​

  • EndoPredict is a second-generation gene expression test for ER-positive HER2-negative (ER+/HER2-) early-stage breast cancer recurrence, offering improved accuracy by combining molecular data with clinical-pathological factors.1,4 Backed by Level 1A evidence in ESMO1 and recommended by key guidelines,13-17 EndoPredict supports informed decisions that reduce overtreatment and long-term impact on patients’ lives.

Available as a CE-marked IVD kit for qualified pathology labs in many countries, it can be performed locally after training and qualification or accessed through our global network of more than 90 partner labs – ensuring fast, reliable results for physicians and patients.

Learn how EndoPredict is performed

Clinicians Trust EndoPredict​®

EndoPredict is an advanced genomic test that pathologists can offer to support individualized treatment planning for early-stage ER+/HER2- breast cancer. Clinicians trust EndoPredict for its reliability and its accurate prognostic and predictive performance – making it a valuable tool in routine practice.​

With just 2.5 hours of hands-on time and a total turnaround of approximately 8 hours, the test fits seamlessly into molecular lab workflows, while ensuring fast result delivery to treating physicians.​

Unlocking Precision - What EndoPredict® Reveals in Its Results

  • Individual 10-year risk of distant recurrence1​
  • Individual likelihood of chemotherapy benefit over 10 years2​
  • Individual risk of late distant recurrence between years 5 and 153​

Discover the detailed insights provided by the EndoPredict result report. Explore the report’s structure, interpret the risk scores, and understand how this information supports personalized treatment decisions.​

Explore the result report

Second-Generation Testing – More Confidence, More Clarity​

EndoPredict is a second-generation gene expression test developed to deliver greater prognostic and predictive accuracy for informed therapy decisions.4,5​

Why Second-Generation Matters​ - EndoPredict goes beyond molecular profiling alone. It combines:

  • 12-Gene Molecular Score – Captures risk of both early and late distant recurrence1,18
  • Clinicopathological Factors – Integrates tumor size and nodal status directly into the result1
  • CE-IVD Kit for Local Testing – Enables fast turnaround and lab-controlled quality within molecular pathology workflows

Pathologists can support confident, guideline-aligned decisions with a test trusted by clinicians worldwide.​

To see how EndoPredict combines molecular and clinical data for precise prognostication, explore our interactive animation app.

EndoPredict App​

Prognostic ability to detect distant recurrence5

The C-Index is a standard statistic used to measure prognostic accuracy. It allows the comparison of different tests independently of their cut-off values. The higher the C-Index, the stronger the prognostic performance of a test.

Proven Superiority in Risk Stratification​

EndoPredict delivers the highest prognostic accuracy for distant breast cancer recurrence.5 It was specifically developed to include genes associated with both early and late metastasis,18 and it integrates clinical-pathological factors to further enhance its predictive performance.1,4 This combined approach provides superior accuracy compared to first-generation tests.5 This enables more precise patient stratification and strengthens the confidence clinicians place in pathology-supported treatment recommendations.
  • Learn more about EndoPredict’s superior accuracy​
Comparing tests​

Evidence you can Trust​

Recommended in major international guidelines, including ASCO, NCCN, AJCC, St. Gallen, and NICE, along with ESMO Level of Evidence 1A recommendation.12-17 It also holds a prominent place in national guidelines worldwide.​

ESMO LoE1A Recommendation for Node Negative and Node Positive Disease​12

EndoPredict is recognized in the actual breast cancer guidelines as test for both pre- and postmenopausal patients. The guideline excludes intermediate-risk results – giving EndoPredict a clear advantage with only low- and high-risk categories for confident chemotherapy decisions.

Highest level of evidence (LoE1A)

Inclusion of premenopausal patients

All patients included due to clear results

View ESMO details

How to Order an EndoPredict® Test for your Patient

EndoPredict breast cancer prognostic and chemotherapy predictive test is available for physicians to order via numerous local labs.

  • 1 Find your local lab

Choose and contact your local pathology lab from our list of certified laboratories performing EndoPredict. Working with a nearby lab ensures the fastest turnaround time for results.

  • 2 Send your sample

Tumor samples from a diagnostic biopsy or surgery specimen (before treatment) can be sent directly to your chosen lab. The laboratory will provide detailed instructions for sample preparation and shipping.

  • 3 Results in days

Once the lab has received your sample, results are typically available within a few days—supporting timely, confident treatment decisions for your patients.

Test Access & ordering

How to Order an EndoPredict® Kit

Pathologists who are already trained and qualified to run EndoPredict in their own laboratory can order kits directly.
Please note: kits are available exclusively for laboratories with established implementation and trained personnel. 

Ressources for performing laboratories

Get the EndoPredict® Test in Your Lab

EndoPredict is available as a CE-marked IVD kit that can be run in local molecular pathology laboratories after a comprehensive onsite training, provided by Eurobio Scientific.

Interested in offering EndoPredict in your lab? Use the contact form below – we’ll evaluate the requirements together.

 

  1. Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin. Cancer Res. 2011
  2. Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
  3. Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019
  4. Buus R. et al.: Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016
  5. Sestak I. et al.: Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018
  6. Constantinidou A. et al.: Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer. Clin. Cancer Res. 2022
  7. Sestak I. et al.: Prognostic Value of EndoPredict in Women with Hormone Receptor Positive, HER2-Negative Invasive Lobular Breast Cancer. Clin Cancer Res. 2020
  8. Klein, E. et al.: Long-term outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor positive, HER2-negative early breast cancer. Breast Cancer Res Treat. 2024
  9. Schmitt, W. D. et al.: Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charité registry. SABCS 2022
  10. Vázquez-Juarez D. et al.: Follow-up of prospective cohort of Mexican premenopausal women with breast cancer who received guided adjuvant treatment with the EndoPredict assay. SABCS 2021

  11. Jung et al.: Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer. Breast Care 2022

  12. Loibl S. et al.: Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023

  13. Andre F. et al.: Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022
  14. Curigliano G. et al.: Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann. Oncol. 2023
  15. AJCC Cancer Staging Manual- Eight Edition 2017
  16. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer r V.4.2024 ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed [July 17, 2024]. To view the most recent and complete version of the guideline, go online to NCCN.org.
  17. National Institute for Health and Care Excellence (2024). Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (Diagnostics guidance [DG58]).
  18. Dubsky P. et al.: The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer. 2013

Buscar en

es_ES
es_ES en_GB fr_FR it_IT de_DE
Ir arriba